trending Market Intelligence /marketintelligence/en/news-insights/trending/DQcCMP_ZtAtcQjXkJPfpFA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Intra-Cellular Therapies prices $295M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Intra-Cellular Therapies prices $295M common stock offering

Intra-Cellular Therapies Inc. priced its public offering of 10 million common shares at $29.50 per share.

The New York-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 1.5 million common shares.

Gross proceeds are expected to be $295 million.

The offer is expected to close Jan. 10.

J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group LLC are acting as joint book-running managers for the offer, while Cantor Fitzgerald & Co. and Canaccord Genuity LLC are acting as co-lead managers. JMP Securities LLC is acting as co-manager for the offering.

Intra-Cellular Therapies develops treatments for neuropsychiatric and neurodegenerative disorders. In December 2019, the U.S. Food and Drug Administration approved its medicine Caplyta to treat adults with schizophrenia.